地舒单抗是否已入医保？

In 2018, (denosumab) was included in the list of overseas new drugs in urgent clinical need (first batch) and entered the fast review channel of the National Medical Products Administration. This approval makes denosumab the first and currently the only drug for the treatment of giant cell tumor of bone, bringing patients an innovative treatment option to control disease progression and improve quality of life.

On May 27, 2019, Amgen China announced that denosumab (denosumab) has been approved by the National Medical Products Administration for the treatment of giant cell tumors of bone that are unresectable or whose surgical resection may cause severe functional disability, including adults and adolescent patients with skeletal maturity (defined as at least 1 mature long bone and weight ≥45 kg).  

Is denosumab covered by medical insurance?

Medical insurance is the most direct way for domestic patients to reduce their financial burden. However, unfortunately, denosumab has not been on the market for a long time, so it is not currently covered by medical insurance. Patients can only purchase it at the full price at the original price.

Desosumab (denosumab) is a drug that targets the RANK ligand. Compared with bisphosphonates that have been clinically used for a long time, denosumab has the advantage of significantly prolonging the occurrence time of bone damage-related events. It can be administered subcutaneously in clinical practice and is easy to use. Desosumab can also effectively reduce the patient's risk of fracture and improve the patient's quality of life.

However, the price of denosumab in China is relatively high, and what should patients who cannot be reimbursed by medical insurance do?

Medical Travel has learned that the most cost-effective product currently on the market is denosumab produced by the American company Amgen and marketed in Turkey. The specification is 125mg/1ml tube/box, and the equivalent price in RMB is about $3,000. Patients in need can further contact the medical companion travel service for more information.

The launch of (denosumab) in my country has brought new treatment options to domestic patients. It is believed that it will also be reimbursed by medical insurance in the near future, bringing good news to more patients.